Comorbid Anxiety* Clinical benefit of TMS for patients with Major Depressive Disorder

- 3- to 37-minute TMS treatment sessions
- Proven effective in reducing the symptoms of anxiety in patients with depression
- Well-established, outpatient procedure
- Noninvasive, no anesthesia








Further details

MagVenture TMS Therapy[®] is the first CE approved TMS solution to include a clinical benefit for comorbid anxiety in patients with Major Depressive Disorder.

Although depression and anxiety are traditionally regarded as separate disorders, they are highly comorbid: 40%–50% of people diagnosed with major depressive disorder will also have symptoms of anxiety, or vice versa.

The efficacy of TMS for comorbid anxiety



¹Graphics by MagVenture, based on: Clarke et al., 2019, Journal of Affective Disorders: Efficacy of repetitive transcranial magnetic stimulation in the treatment of depression with comorbid anxiety disorders

TMS for depression with anxiety symptoms

MagVenture TMS Therapy[®] is an advanced neuromodulation technology that uses magnetic pulses to stimulate the affected areas in the brain.

TMS therapy is an effective treatment option for patients with Major Depressive Disorder.

In addition, MagVenture TMS Therapy[®] can reduce the symptoms of comorbid anxiety in patients suffering from depression. Most common side effects are head-ache and nausea.

The total treatment time is 20-30 sessions in total, once per day, five times per week:

- 3 or 37 minutes over the left side of the head (left-DLPFC) or
- 8 minutes applied on the right side (right-DLPFC).



Need more information?

MagVenture offers solutions ranging from the simplest systems to high-performance setups tailored for high patient throughput and upgradable for possible future indications. MagVenture products are available worldwide through direct sales subsidiaries in Germany, the UK, the US, and Brazil and represented in over 55 countries through carefully selected global partners.

> To find out more, please contact MagVenture directly at info@magventure.com or simply visit www.magventure.com

CE Approval & Clinical Benefit

*MagVenture TMS Therapy[®] is indicated for the "Treatment of Major Depressive Disorder (MDD) in adult patients who have failed to achieve satisfactory improvement from two prior antidepressant medications, at or above the minimal effective dose and duration in the current episode."

For subjects responding to the treatment of MDD, who have symptoms of comorbid anxiety, the clinical benefit can additionally include an improvement of anxiety symptoms.

